Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

a rodent model;

-- Silencing of KSP mRNA in vivo by greater than 50 percent after a single injection of a KSP-specific siRNA in a rodent model; and

-- Halting of human cancer cell proliferation in vitro when KSP was silenced by a target-specific siRNA.

Alnylam's RNAi therapeutic, ALN-VSP01, is comprised of two small interfering RNAs, or siRNAs, the molecules that mediate RNAi. Each siRNA targets a distinct and well-validated gene in the growth and proliferation of tumors: VEGF, a key mediator of tumor angiogenesis; and KSP, a protein required for cell division that, when inhibited, leads to cell arrest and cell death in dividing cells. ALN-VSP01 is formulated using Alnylam's novel liposomal formulation technology, which has been used to achieve delivery of siRNAs to cells of the liver and efficient silencing of genes expressed in that organ. Liposomal delivery can also be optimized for delivery to other organs and tumor types, such that ALN-VSP01 may ultimately have potential for a range of solid tumors. Alnylam's collaborator, Inex Pharmaceuticals Corporation, is manufacturing the lipid-based formulation as the company prepares for pre-IND toxicology studies with ALN-VSP01.

"Despite many advances in the treatment of cancer with targeted small molecules and antibody therapeutics, the clinical impact of these therapies is generally measured in only months of survival benefit. New modalities like RNAi therapeutics offer the potential to advance cancer therapy to a whole new level," said George D. Demetri, M.D., of Dana-Farber Cancer Institute and Harvard Medical School. "I'm encouraged by Alnylam's pre-clinical data demonstrating the ability to silence disease pathway genes with delivery of RNAi therapeutics, and believe that the application of this approach for the treatment of primary and secondary liver cancers holds considerable promise."

About Liver Cancer

Primary liver cancer is cancer that forms in the tissues of the l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... 2015  Growth of the U.S. nonprescription market is ... prescription users to the OTC market. Due to an ... Rx-to-OTC switch activity over the next five years with ... new brands entering the market into existing categories. ... years (even those with low to moderate likelihood), the ...
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... Those looking to catch a new and refreshing show on Broadway, look no ... and achievements including an Obie Award, Outer Critics Circle Award, Drama Desk Award, Lucille ...
(Date:7/31/2015)... ... July 31, 2015 , ... Cosmetic Town has proven itself ... various plastic surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and ... Botox and fillers. , Staying up to date with the latest cosmetic ...
(Date:7/31/2015)... ... 2015 , ... “Engage: Don’t Just Age” will be the ... symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort Casino in ... executives, administrators, directors of nursing, rehabilitation managers and other management and corporate personnel ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), ... we treat aging diseases. , BioViva announces it has begun a fundraiser through ... Alzheimer’s Disease (AD) and find a cure. MaxLife will grant 100% of the money ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3
... Feb. 3 When Americans are asked about the ... Poll, commissioned by the,National Court Appointed Special Advocate (CASA) ... nothing about the experiences of children in,foster care, and ... these,children. When adults do think of children in ...
... and PACS Industry Veteran , Shawn Gibbons ... Compressus, Inc., leaders in healthcare IT systems interoperability ... of Janine Broda to chief marketing officer and ... president and general manager of the MEDxConnect(TM) division.Proven ...
... -- Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ... and distributor of high-quality,pharmaceutical grade glucose products ... invited to make a corporate presentation at ... Conference. , This ...
... are found to slow damage , , TUESDAY, Feb. 3 ... loss caused by Alzheimer,s disease, a new study says. ... University found that insulin acts as a shield that deflects ... responsible for forming memories. , "Therapeutics designed to ...
... Mich., Feb. 3 Perrigo Company,(Nasdaq: PRGO ; TASE) today announced results for its fiscal year 2009 second,quarter and six months that ended December 27, 2008. ... Perrigo Company, (in ... Second Quarter Six Months, ... 2009 2008 2009 ...
... MOUNTAIN VIEW, Calif., Feb. 3 MAP Pharmaceuticals, ... that the waiting period under the Hart-Scott-Rodino Act ... with AstraZeneca has expired, and the agreement is ... AstraZeneca will jointly develop and commercialize UDB, MAP ...
Cached Medicine News:Health News:National CASA Association Aims to Eliminate the Foster Care Stigma 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 2Health News:Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference 3Health News:Insulin May Protect Against Alzheimer's 2Health News:Perrigo Reports Record Second Quarter Sales 2Health News:Perrigo Reports Record Second Quarter Sales 3Health News:Perrigo Reports Record Second Quarter Sales 4Health News:Perrigo Reports Record Second Quarter Sales 5Health News:Perrigo Reports Record Second Quarter Sales 6Health News:Perrigo Reports Record Second Quarter Sales 7Health News:Perrigo Reports Record Second Quarter Sales 8Health News:Perrigo Reports Record Second Quarter Sales 9Health News:Perrigo Reports Record Second Quarter Sales 10Health News:Perrigo Reports Record Second Quarter Sales 11Health News:Perrigo Reports Record Second Quarter Sales 12Health News:Perrigo Reports Record Second Quarter Sales 13Health News:Perrigo Reports Record Second Quarter Sales 14Health News:Perrigo Reports Record Second Quarter Sales 15Health News:Perrigo Reports Record Second Quarter Sales 16Health News:Perrigo Reports Record Second Quarter Sales 17Health News:Perrigo Reports Record Second Quarter Sales 18Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 2Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 3Health News:MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca 4
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
The Medtronic® Resting Heart™ System offers a new approach to reducing cardiac surgery morbidity....
This adapter features a female luer on the single leg. A rigid "Y" has two legs with white clamps and terminate with male luers....
Medicine Products: